Valuation: ABVC BioPharma, Inc.

Market Cap 27.26M 24.38M 22.55M 20.42M 38.22M 2.59B 38.85M 271M 107M 1.36B 102M 100M 4.3B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 29.99M 26.82M 24.81M 22.46M 42.04M 2.85B 42.73M 299M 118M 1.49B 113M 110M 4.73B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
1 day+0.96%
1 week+15.38%
Current month-0.94%
1 month-7.08%
3 months-8.70%
6 months-1.87%
Current year-50.70%
1 week 0.96
Extreme 0.95995
1.07
1 month 0.89
Extreme 0.8918
1.14
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.06
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 21/06/2023
Chief Tech/Sci/R&D Officer 72 15/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
20/5/22 Other

Chairman

7,908,805 26.0954%
2/8/21 Other

Director

5,949 0.0243%
2/8/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%+15.38%-64.77%-17.97% 27.26M
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.69%-0.67%+9.06%+76.30% 54.57B
-0.22%+1.34%+9.47%+101.34% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.84%+14.87%+59.84%+48.93% 26.5B
Average -0.89%+3.68%+37.04%+131.63% 38.33B
Weighted average by Cap. -0.90%+2.28%+45.60%+148.31%

Financials

2024 2025
Net sales 510K 456K 422K 382K 714K 48.48M 726K 5.07M 2.01M 25.36M 1.91M 1.87M 80.29M -
Net income -4.9M -4.38M -4.06M -3.67M -6.87M -466M -6.99M -48.81M -19.31M -244M -18.4M -18.01M -772M -7.91M -7.07M -6.54M -5.92M -11.09M -752M -11.27M -78.73M -31.14M -394M -29.68M -29.05M -1.25B
Net Debt 2.88M 2.58M 2.38M 2.16M 4.04M 274M 4.11M 28.69M 11.35M 143M 10.82M 10.59M 454M 2.73M 2.44M 2.26M 2.04M 3.82M 259M 3.89M 27.15M 10.74M 136M 10.24M 10.02M 430M
Projected Income Statement - Annual - ABVC BioPharma, Inc.
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
26/10/26 USD 1.050 +0.96% 36,596
23/10/26 USD 1.040 -0.70% 22,011
22/10/26 USD 1.047 +4.73% 45,691
21/10/26 USD 1.000 +7.53% 49,336
20/10/26 USD 0.9300 +2.20% 11,820
  1. Stock Market
  2. Stocks
  3. ABVC Stock